AtheroGenics, Inc.

AtheroGenics, Inc.

April 24, 2007 13:29 ET

AtheroGenics to Present at Morgan Stanley Global Healthcare Unplugged Conference on May 2, 2007

ATLANTA, GA--(CCNMatthews - April 24, 2007) - AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced its participation in the upcoming 2007 Morgan Stanley Global Healthcare Conference on Wednesday, May 2, 2007, at 3:45 p.m. EDT at The Ritz-Carlton in Key Biscayne, Florida.

The conference will feature its "Unplugged" presentation format with Morgan Stanley analysts hosting company management in an informal and interactive discussion with the investment community.

Attending from AtheroGenics will be Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer and Mark P. Colonnese, Executive Vice President Commercial Operations and Chief Financial Officer.

A live audio webcast of the presentation will be available on the AtheroGenics Investor Relations Events website at A replay of the presentation will be available on the Company's website approximately twenty-four hours after the presentation and will be archived for thirty days.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. AtheroGenics' lead compound, AGI-1067, has completed a Phase III clinical trial as an oral therapy for the treatment of atherosclerosis. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant® technology. For more information about AtheroGenics, please visit

Contact Information